tegafur has been researched along with Hepatocellular Carcinoma in 149 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is the sole molecular-targeted agent showing a survival benefit in patients with advanced hepatocellular carcinoma (HCC)." | 9.19 | A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma. ( Arai, K; Chiba, T; Kanai, F; Kaneko, S; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yamashita, T; Yokosuka, O, 2014) |
| "Sorafenib is a multi-kinase inhibitor, which was approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)." | 9.16 | Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ( Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS, 2012) |
| "The aim was to determine the recommended dose of combined chemotherapy with mitoxantrone and uracil/tegafur (Phase I part) and to clarify its efficacy and safety in patients with advanced hepatocellular carcinoma at the recommended dose (Phase II part)." | 9.15 | A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Suzuki, E; Ueno, H, 2011) |
| "Sorafenib plus metronomic tegafur/uracil therapy can induce tumor stabilization in advanced hepatocellular carcinoma (HCC) patients." | 9.15 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Hsu, CY; Hu, FC; Shen, YC; Shih, TT; Wei, SY; Yu, CW, 2011) |
| "Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 9.14 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010) |
| "A prospective randomized trial was conducted to evaluate the efficacy of long-term oral administration of low-dose tegafur combined with uracil as an adjuvant chemotherapy, following transcatheter arterial embolization (TAE) in 40 patients with hepatocellular carcinoma (HCC)." | 9.08 | A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. ( Arase, Y; Chayama, K; Ikeda, K; Koida, I; Kumada, H; Saitoh, S; Tsubota, A, 1995) |
| "We report a case of multiple lung metastases from hepatocellular carcinoma(HCC)successfully treated by oral administration of tegafur/uracil(UFT)." | 8.89 | [Complete remission of hepatocellular carcinoma with multiple lung metastases by oral administration of tegafur/uracil]. ( Hatano, E; Koyama, Y; Takada, Y; Tanabe, K; Taura, K; Uemoto, S, 2013) |
| "Sorafenib and conventional systemic cytotoxicity chemotherapy are currently being used in parallel for the patients with advanced hepatocellular carcinoma (HCC)." | 7.80 | Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma. ( Hu, X; Li, Q; Li, Y; Liang, R; Liao, S; Liao, X; Lin, Y; Liu, Z; Lv, Y; Yuan, C; Zhang, J, 2014) |
| "Sorafenib and S-1 (one mixed formulation containing 5-FU prodrug and dihydropyrimidine dehydrogenase inhibitor) were two effective agents against hepatocellular carcinoma (HCC), but whether they had synergistic effects remained unclear." | 7.79 | Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1. ( Cai, JP; Hao, XY; Hou, X; Lai, YR; Liang, LJ; Yin, XY; Zhai, JM; Zhang, LJ, 2013) |
| "Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment." | 7.79 | Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013) |
| "Multidrug resistant H22 (H22/FAP) hepatocellular carcinoma cells were produced in vitro by continuous exposure to increasing doses of doxorubicin, cisplatin and 5-fluorouracil (FAP regimen)." | 7.79 | Association between reversal of multidrug resistance by methyl jasmonate and P-glycoprotein ATPase activity in hepatocellular carcinoma. ( Huang, FZ; Jiang, XZ; Liu, XY; Nie, WP; Wang, CF; Wang, YQ, 2013) |
| "A 65-year-old woman who had diffuse hepatocellular carcinoma(HCC)with tumor thrombus of right portalvein(Vp3) and lung metastases(Stage IVB)was treated by single-agent therapy with tegafur/uracil(UFT)." | 7.76 | [A case of hepatocellular carcinoma with portal vein thrombus(Vp3)and lung metastases(stage IVB),which responded completely to treatment with Tegafur/Uracil]. ( Adachi, K; Hiramatsu, S; Kurai, O; Miyano, M; Oka, H; Sasaki, E; Yamasaki, T, 2010) |
| "We report the successful treatment of multiple lung metastases after hepatic resection for hepatocellular carcinoma (HCC) with combined docetaxel, cisplatin (CDDP), and enteric-coated tegafur/uracil (UFT-E)." | 7.75 | Successful treatment of multiple lung metastases of hepatocellular carcinoma by combined chemotherapy with docetaxel, cisplatin and tegafur/uracil. ( Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2009) |
| "We herein report the complete remission of multiple recurrent hepatocellular carcinomas (HCCs) by the oral administration of tegafur/uracil (UFT) alone." | 7.75 | Complete remission of multiple recurrent hepatocellular carcinomas by oral administration of enteric-coated tegafur/uracil in a patient with huge hepatocellular carcinoma extending to the inferior vena cava after hepatic resection: analysis of mRNA expres ( Asakawa, M; Fujii, H; Kono, H; Matsuda, M; Shiba, S, 2009) |
| "We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil." | 7.74 | Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007) |
| "We report a case of advanced hepatocellular carcinoma (HCC) successfully controlled by the suppository administration of Tegafur alone." | 7.70 | [A case of advanced hepatocellular carcinoma responding to suppository of Tegafur]. ( Arakawa, A; Kudo, K; Nishimura, R; Takagi, Y; Takahashi, M; Yamashita, Y, 1998) |
| "We report a case of complete remission of multiple hepatocellular carcinomas after oral administration of enteric-coated tegafur/uracil." | 7.70 | Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. ( Asakura, H; Ebe, Y; Ichida, T; Ishikawa, T; Ishimoto, Y; Naito, M; Nomoto, M; Usuda, H; Yokoyama, J, 1999) |
| "We report a case of advanced hepatocellular carcinoma (HCC), successfully treated by a combination therapy of alpha-interferon (IFN-alpha) and tegafur/uracil (UFT)." | 7.70 | Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of alpha-interferon and oral tegafur/uracil. ( Dono, K; Eguchi, H; Gotoh, M; Kishimoto, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K, 2000) |
| "A 46-year-old male (performance status 1) with hepatocellular carcinoma (HCC), which diffusely involved the anterior segment of the right lobe, occluded the second portal branch and metastased to the left lobe (stage IV-A), was on combined therapy with TAE of lipiodol (LPD), mitomycin C (MMC) 10 mg and gelatin sponge at the time of angiography on March 16, 1987." | 7.67 | [Successful therapy with tegafur and lentinan after TAE for hepatocellular carcinoma--a case report]. ( Inagaki, Y; Miyairi, M; Miyamoto, K, 1989) |
| " In 22 resected patients with hepatocellular carcinoma (HCC), the concentrations of 5-fluorouracil (5-FU), tegafur and uracil were estimated in the serum, liver and cancer tissues after oral administration of UFT (tegafur, 300mg) before operation." | 7.67 | [5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration]. ( Suenaga, M, 1987) |
| "A Phase II study of co-administration of uracil and tegafur (UFT) was performed in 32 patients with unresectable hepatocellular carcinoma." | 7.67 | Phase II study of co-administration of uracil and tegafur (UFT) in hepatocellular carcinoma. Tokyo Liver Cancer Chemotherapy Study Group. ( , 1985) |
| "The pharmacokinetics of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) and its conversion into 5-fluorouracil (FUra) in liver tissue were studied in ten patients with hepatocellular carcinoma (HCC)." | 7.67 | Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ( Imai, Y; Kawata, S; Minami, Y; Miyoshi, S; Noda, S; Saitoh, R; Tamura, S; Tarui, S, 1987) |
| "Recurrence of hepatocellular carcinoma (HCC) after surgery is frequent, and is an important factor adversely influencing the long-term survival of patients." | 6.82 | Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial. ( Ishizuka, M; Iso, Y; Kato, M; Kubota, K; Nemoto, T; Shimoda, M; Tago, K, 2016) |
| "From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil." | 6.73 | Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p ( Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2007) |
| "Frequent recurrence of hepatocellular carcinoma (HCC) after surgery remains a major clinical problem." | 6.72 | Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. ( Hasegawa, K; Ijichi, M; Imamura, H; Kokudo, N; Makuuchi, M; Matsuyama, Y; Sano, K; Sugawara, Y; Takayama, T, 2006) |
| "Twenty-one patients with advanced hepatocellular carcinoma were randomly divided into two groups." | 6.69 | [Effect of indomethacin on natural killer(NK) cell and T lymphocyte subsets from patients with hepatocellular carcinoma]. ( Chen, FY; Yuan, WJ; Zhang, GY, 2000) |
| "Patients with hepatocellular carcinoma (HCC) are highly compromised by failing liver function." | 6.68 | A pharmacological pilot study: application of an intermittent schedule of oral uracil and ftorafur (UFT) for hepatocellular carcinoma patients. ( Haneda, T; Kamiyama, T; Nakanishi, K; Nishibe, M; Shimamura, T; Uchino, J; Une, Y, 1996) |
| "Pretreatment with tocopheryl nicotinate and indomethacin increased the K values in the control subjects, but was without effect on the K values in patients with primary hepatoma." | 5.26 | Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma. ( Hobara, N; Watanabe, A, 1979) |
| "Sorafenib is the sole molecular-targeted agent showing a survival benefit in patients with advanced hepatocellular carcinoma (HCC)." | 5.19 | A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma. ( Arai, K; Chiba, T; Kanai, F; Kaneko, S; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yamashita, T; Yokosuka, O, 2014) |
| "Sorafenib is a multi-kinase inhibitor, which was approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)." | 5.16 | Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ( Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS, 2012) |
| "The aim was to determine the recommended dose of combined chemotherapy with mitoxantrone and uracil/tegafur (Phase I part) and to clarify its efficacy and safety in patients with advanced hepatocellular carcinoma at the recommended dose (Phase II part)." | 5.15 | A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Suzuki, E; Ueno, H, 2011) |
| "Sorafenib plus metronomic tegafur/uracil therapy can induce tumor stabilization in advanced hepatocellular carcinoma (HCC) patients." | 5.15 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. ( Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Hsu, CY; Hu, FC; Shen, YC; Shih, TT; Wei, SY; Yu, CW, 2011) |
| "Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was recently approved for the treatment of advanced hepatocellular carcinoma (HCC)." | 5.14 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. ( Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC, 2010) |
| "A prospective randomized trial was conducted to evaluate the efficacy of long-term oral administration of low-dose tegafur combined with uracil as an adjuvant chemotherapy, following transcatheter arterial embolization (TAE) in 40 patients with hepatocellular carcinoma (HCC)." | 5.08 | A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. ( Arase, Y; Chayama, K; Ikeda, K; Koida, I; Kumada, H; Saitoh, S; Tsubota, A, 1995) |
| "Uracil (UFT) was administrated to 90 patients with advanced hepatocellular carcinoma for whom transcatheter arterial embolization was applied." | 5.07 | [Randomized trial-comparing UFT and FT in the treatment of advanced hepatocellular carcinoma (second report: well controlled study on patients with transcatheter arterial embolization) Osaka Research Society for Liver, Gallbladder and Pancreas]. ( Kamata, T; Kojima, J; Monna, T, 1992) |
| "In a randomized trial, Tegafur (FT-207) or Tegafur-Uracil (UFT) was administrated to 76 patients with advanced hepatocellular carcinoma for whom transcatheter arterial embolization could not be applied." | 5.06 | [Randomized trial comparing UFT and FT-207 in the treatment of advanced hepatocellular carcinoma (first report: well controlled study on the patients for whom transcatheter arterial embolization could not be applied) Osaka Research Society for Liver, Gall ( Kamata, T; Kojima, J; Monna, T, 1990) |
| "We report a case of multiple lung metastases from hepatocellular carcinoma(HCC)successfully treated by oral administration of tegafur/uracil(UFT)." | 4.89 | [Complete remission of hepatocellular carcinoma with multiple lung metastases by oral administration of tegafur/uracil]. ( Hatano, E; Koyama, Y; Takada, Y; Tanabe, K; Taura, K; Uemoto, S, 2013) |
| "Sorafenib and conventional systemic cytotoxicity chemotherapy are currently being used in parallel for the patients with advanced hepatocellular carcinoma (HCC)." | 3.80 | Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma. ( Hu, X; Li, Q; Li, Y; Liang, R; Liao, S; Liao, X; Lin, Y; Liu, Z; Lv, Y; Yuan, C; Zhang, J, 2014) |
| "Sorafenib and S-1 (one mixed formulation containing 5-FU prodrug and dihydropyrimidine dehydrogenase inhibitor) were two effective agents against hepatocellular carcinoma (HCC), but whether they had synergistic effects remained unclear." | 3.79 | Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1. ( Cai, JP; Hao, XY; Hou, X; Lai, YR; Liang, LJ; Yin, XY; Zhai, JM; Zhang, LJ, 2013) |
| "Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment." | 3.79 | Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013) |
| "Multidrug resistant H22 (H22/FAP) hepatocellular carcinoma cells were produced in vitro by continuous exposure to increasing doses of doxorubicin, cisplatin and 5-fluorouracil (FAP regimen)." | 3.79 | Association between reversal of multidrug resistance by methyl jasmonate and P-glycoprotein ATPase activity in hepatocellular carcinoma. ( Huang, FZ; Jiang, XZ; Liu, XY; Nie, WP; Wang, CF; Wang, YQ, 2013) |
| " We investigated the therapeutic efficacies of metronomic S-1, an oral 5-fluorouracil prodrug, and vandetanib, an epidermal growth factor receptor and vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, in models of hepatocellular carcinoma (HCC)." | 3.77 | Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. ( Abe, M; Hashimoto, O; Inoue, K; Iwamoto, H; Kerbel, RS; Koga, H; Kurogi, J; Kuwahara, R; Nakamura, T; Niizeki, T; Sata, M; Torimura, T; Ueno, T; Yano, H, 2011) |
| "A 65-year-old woman who had diffuse hepatocellular carcinoma(HCC)with tumor thrombus of right portalvein(Vp3) and lung metastases(Stage IVB)was treated by single-agent therapy with tegafur/uracil(UFT)." | 3.76 | [A case of hepatocellular carcinoma with portal vein thrombus(Vp3)and lung metastases(stage IVB),which responded completely to treatment with Tegafur/Uracil]. ( Adachi, K; Hiramatsu, S; Kurai, O; Miyano, M; Oka, H; Sasaki, E; Yamasaki, T, 2010) |
| "Here, we present a case of recurrent hepatocellular carcinoma(HCC)with portal thrombus that disappeared within only two months by oral tegafur(UFT-E)." | 3.75 | [A case report--complete disappearance of multiple intrahepatic recurrences and portal thrombus in a case of hepatocellular carcinoma treated with UFT-E]. ( Anegawa, G; Hayashi, H; Inoue, F; Sonoda, H, 2009) |
| "We report the successful treatment of multiple lung metastases after hepatic resection for hepatocellular carcinoma (HCC) with combined docetaxel, cisplatin (CDDP), and enteric-coated tegafur/uracil (UFT-E)." | 3.75 | Successful treatment of multiple lung metastases of hepatocellular carcinoma by combined chemotherapy with docetaxel, cisplatin and tegafur/uracil. ( Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2009) |
| "We herein report the complete remission of multiple recurrent hepatocellular carcinomas (HCCs) by the oral administration of tegafur/uracil (UFT) alone." | 3.75 | Complete remission of multiple recurrent hepatocellular carcinomas by oral administration of enteric-coated tegafur/uracil in a patient with huge hepatocellular carcinoma extending to the inferior vena cava after hepatic resection: analysis of mRNA expres ( Asakawa, M; Fujii, H; Kono, H; Matsuda, M; Shiba, S, 2009) |
| "We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil." | 3.74 | Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007) |
| "We report a patient with hepatocellular carcinoma (HCC) with intraperitoneal lymph node metastases in whom UFT (uracil + tegafur) was markedly effective." | 3.71 | [A patient with hepatocellular carcinoma with intraperitonial lymph node metastases in whom oral UFT treatment was markedly effective]. ( Baba, Y; Imamura, Y; Kubozono, O; Maenohara, S; Moriya, H; Ogura, Y; Tahara, K, 2002) |
| "We report a case of advanced hepatocellular carcinoma (HCC) successfully controlled by the suppository administration of Tegafur alone." | 3.70 | [A case of advanced hepatocellular carcinoma responding to suppository of Tegafur]. ( Arakawa, A; Kudo, K; Nishimura, R; Takagi, Y; Takahashi, M; Yamashita, Y, 1998) |
| "We report a case of complete remission of multiple hepatocellular carcinomas after oral administration of enteric-coated tegafur/uracil." | 3.70 | Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. ( Asakura, H; Ebe, Y; Ichida, T; Ishikawa, T; Ishimoto, Y; Naito, M; Nomoto, M; Usuda, H; Yokoyama, J, 1999) |
| "We report a case of advanced hepatocellular carcinoma (HCC), successfully treated by a combination therapy of alpha-interferon (IFN-alpha) and tegafur/uracil (UFT)." | 3.70 | Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of alpha-interferon and oral tegafur/uracil. ( Dono, K; Eguchi, H; Gotoh, M; Kishimoto, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K, 2000) |
| "UFT was administered preoperatively in 20 cases of primary hepatocellular carcinoma, and tegafur, 5-fluorouracil (5-FU), uracil, total thymidylate synthase (TS) and free TS in blood and liver tissue were determined." | 3.67 | [Study on the pharmacokinetics of UFT in patients with hepatocellular carcinoma associated with cirrhosis]. ( Ito, Y; Matsuoka, S; Misawa, K; Nagafuchi, E; Nakajima, Y; Ogasawara, K; Sato, N; Uchino, J; Une, Y, 1989) |
| "A 46-year-old male (performance status 1) with hepatocellular carcinoma (HCC), which diffusely involved the anterior segment of the right lobe, occluded the second portal branch and metastased to the left lobe (stage IV-A), was on combined therapy with TAE of lipiodol (LPD), mitomycin C (MMC) 10 mg and gelatin sponge at the time of angiography on March 16, 1987." | 3.67 | [Successful therapy with tegafur and lentinan after TAE for hepatocellular carcinoma--a case report]. ( Inagaki, Y; Miyairi, M; Miyamoto, K, 1989) |
| " In 22 resected patients with hepatocellular carcinoma (HCC), the concentrations of 5-fluorouracil (5-FU), tegafur and uracil were estimated in the serum, liver and cancer tissues after oral administration of UFT (tegafur, 300mg) before operation." | 3.67 | [5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration]. ( Suenaga, M, 1987) |
| "A Phase II study of co-administration of uracil and tegafur (UFT) was performed in 32 patients with unresectable hepatocellular carcinoma." | 3.67 | Phase II study of co-administration of uracil and tegafur (UFT) in hepatocellular carcinoma. Tokyo Liver Cancer Chemotherapy Study Group. ( , 1985) |
| "The pharmacokinetics of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) and its conversion into 5-fluorouracil (FUra) in liver tissue were studied in ten patients with hepatocellular carcinoma (HCC)." | 3.67 | Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ( Imai, Y; Kawata, S; Minami, Y; Miyoshi, S; Noda, S; Saitoh, R; Tamura, S; Tarui, S, 1987) |
| "Tegafur fine granule preparation orally administered to the patients with primary hepatoma and liver cirrhosis, and the concentration of tegafur and 5-fluorouracil in the blood were determined." | 3.66 | [Sequential changes in blood concentrations of tegafur and 5-FU during oral administration of fine granules of tegafur in patients with primary liver cancer]. ( Hattori, M; Horiike, N; Kanaoka, M; Ohta, Y; Onji, M; Yamashita, Y; Yoshida, T, 1982) |
| "Unresectable advanced hepatocellular carcinoma is a heterogeneous disease, for which sorafenib is the first targeted agent approved for first-line therapy, and treatment options for patients with sorafenib-refractory advanced hepatocellular carcinoma are limited." | 2.84 | S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. ( Date, Y; Fang, X; Furuse, J; Hidaka, H; Ikeda, M; Kaneko, S; Kawazoe, S; Kudo, M; Moriguchi, M; Numata, K; Ohkawa, S; Okusaka, T; Sato, Y; Takeuchi, M; Tanaka, H, 2017) |
| "Recurrence of hepatocellular carcinoma (HCC) after surgery is frequent, and is an important factor adversely influencing the long-term survival of patients." | 2.82 | Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial. ( Ishizuka, M; Iso, Y; Kato, M; Kubota, K; Nemoto, T; Shimoda, M; Tago, K, 2016) |
| " We determined the recommended dosage for CDDP-TAI plus S-1 combination therapy for advanced HCC." | 2.79 | Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial. ( Hosoi, H; Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Okusaka, T; Shimizu, S; Terazawa, T; Ueno, H, 2014) |
| " The common adverse drug reactions were a decrease in hemoglobin levels, hypoalbuminemia, and anorexia, which were mild in severity (grades 1-2)." | 2.79 | Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma. ( Arioka, H; Asaoka, Y; Ikeda, M; Koike, K; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Sakamoto, Y; Shiina, S; Shimizu, S; Tateishi, R; Ueno, H, 2014) |
| "From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil." | 2.73 | Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p ( Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2007) |
| "Frequent recurrence of hepatocellular carcinoma (HCC) after surgery remains a major clinical problem." | 2.72 | Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. ( Hasegawa, K; Ijichi, M; Imamura, H; Kokudo, N; Makuuchi, M; Matsuyama, Y; Sano, K; Sugawara, Y; Takayama, T, 2006) |
| "Twenty-one patients with advanced hepatocellular carcinoma were randomly divided into two groups." | 2.69 | [Effect of indomethacin on natural killer(NK) cell and T lymphocyte subsets from patients with hepatocellular carcinoma]. ( Chen, FY; Yuan, WJ; Zhang, GY, 2000) |
| "Patients with hepatocellular carcinoma (HCC) are highly compromised by failing liver function." | 2.68 | A pharmacological pilot study: application of an intermittent schedule of oral uracil and ftorafur (UFT) for hepatocellular carcinoma patients. ( Haneda, T; Kamiyama, T; Nakanishi, K; Nishibe, M; Shimamura, T; Uchino, J; Une, Y, 1996) |
| "Apatinib is a novel and highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2." | 2.55 | Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. ( Kong, L; Kou, P; Shao, W; Wang, H; Yu, J; Zhang, J; Zhang, Y; Zhu, H, 2017) |
| "The prognosis for hepatocellular carcinoma with extrahepatic metastasis or vascular invasion is very poor." | 2.47 | [A successful case of systemic chemotherapy followed by liver resection for advanced hepatocellular carcinoma with highly vascular invasion and multiple pulmonary metastases]. ( Kakisaka, T; Kamachi, H; Kamiyama, T; Matsushita, M; Mizukami, T; Nakanishi, K; Tahara, M; Taniguchi, M; Todo, S; Yokoo, H, 2011) |
| "The preoperative diagnosis was giant hepatocellular carcinoma (HCC) of the right hepatic anterior region, and extended anterior segmentectomy of the liver was performed." | 2.42 | [Complete disappearance with oral UFT administration of recurrent hepatocellular carcinoma of the remnant liver and multiple lung metastasis after hepatic resection]. ( Hanazaki, K; Kawasaki, S; Kobayashi, A; Matsushita, A; Misawa, R; Miwa, S; Miyagawa, S; Nakagawa, K; Nakata, T; Noike, T; Nomura, K, 2003) |
| "Fluorouracil has been used for a long time, remission rates reported range from 0% to 80%." | 2.36 | [Chemotherapy of gastrointestinal tumors (review of the literature)]. ( Mayr, AC, 1978) |
| "Sorafenib treatment was discontinued." | 1.72 | A case of hepatocellular carcinoma with long-term survival by multidisciplinary treatment for cranial and skeletal muscle metastases. ( Akutsu, N; Hirano, T; Ishigami, K; Kawakami, Y; Nakase, H; Numata, Y; Sasaki, S; Wagatsuma, K, 2022) |
| "Tegafur-uracil has been reported to have only minor adverse effects and is associated with liver injury in 1." | 1.46 | Tegafur-uracil-induced rapid development of advanced hepatic fibrosis. ( Fujiya, M; Hasebe, T; Honda, S; Nakajima, S; Okumura, T; Sawada, K, 2017) |
| "The tumor was diagnosed as hepatocellular carcinoma by MRI and CT." | 1.42 | [Six-year survival with recurrent intrahepatic cholangiocarcinoma achieved by simple S-1 administration]. ( Hirose, T; Ishikawa, Y; Kitamura, K; Miki, A; Minami, T; Morioka, H; Nishihira, T; Otani, T; Suzuki, T; Yoshitani, S, 2015) |
| "Although there was no progression of gastric cancer, medication of S-1 was discontinued." | 1.40 | [Treatment of repeat TACE plus S-1 for multiple intrahepatic recurrence of hepatoma and gastric cancer]. ( Fujisaki, S; Sakurai, K; Takashina, M; Takayama, T; Tomita, R, 2014) |
| "A 44-year-old man with advanced hepatocellular carcinoma (HCC) was admitted to our institution." | 1.39 | [A case of hepatocellular carcinoma (Vp4)-combination therapy prolonged survival in a patient with advanced hepatocellular carcinoma with a tumor thrombus in the portal vein trunk]. ( Kanbara, Y; Tai, K; Terai, S, 2013) |
| "Patients with liver cirrhosis or hepatocellular carcinoma (HCC) have decreased serum insulin-like growth factor (IGF)-1 levels." | 1.38 | Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. ( Cheng, AL; Hsu, CH; Huang, CC; Lin, SD; Shao, YY, 2012) |
| "The patient was diagnosed with hepatocellular carcinoma during work-up for hepatic dysfunction." | 1.38 | [A case of diffuse hepatocellular carcinoma(Vp4) treated by right hepatic trisegmentectomy and multidisciplinary therapy regimens]. ( Kametaka, H; Koyama, T; Makino, H; Seike, K, 2012) |
| "He was an HBV carrier, and hepatocellular carcinoma (HCC) was detected for the first time in 2000." | 1.37 | [Retroperitoneal metastasis of hepatocellular carcinoma - a case report]. ( Kameda, R; Kanazawa, A; Kobayashi, S; Miyakawa, K; Morinaga, S; Ohkawa, S; Tamura, S; Ueno, M; Yamamoto, N, 2011) |
| "A 77-year-old man was diagnosed as hepatocellular carcinoma, and was referred to our hospital." | 1.37 | [A case of complete response to interferon-α and S-1 combination therapy for multiple pulmonary recurrences of hepatocellular carcinoma after hepatic resection]. ( Doki, Y; Eguchi, H; Katsura, Y; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H; Wakasa, K, 2011) |
| "A case of a 68-year-old man with hepatocellular carcinoma (HCC) is presented." | 1.37 | [A case of successful surgical resection followed by S-1 administration for hepatocellular carcinoma with lung metastases and a tumor thrombus into right atrium]. ( Doki, Y; Eguchi, H; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2011) |
| "The treatment for hepatocellular carcinoma with distant metastasis remains unclear." | 1.36 | [A successful case of S-1 chemotherapy for bilateral pulmonary recurrence of hepatocellular carcinoma long after hepatectomy]. ( Fukumori, D; Kamachi, H; Kamiyama, T; Matsushita, M; Nakanishi, K; Tahara, M; Todo, S; Yokoo, H, 2010) |
| "We report a case of hepatocellular carcinoma (HCC) in association with autoimmune hepatitis (AIH)." | 1.36 | [A case of hepatocellular carcinoma with autoimmune hepatitis showing marked reduction of tumors by oral administration of UFT-E]. ( Aizawa, N; Enomoto, H; Hirota, S; Iijima, H; Ikeda, N; Imanishi, H; Ishii, A; Iwai, T; Iwata, Y; Nishiguchi, S; Saito, M; Sakai, Y; Shimomura, S; Takashima, T; Tanaka, H; Yamamoto, T; Yoh, K; Yoshikawa, S, 2010) |
| "There is no standard treatment for hepatocellular carcinoma (HCC) patients with extrahepatic metastases." | 1.35 | Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases. ( Aikata, H; Azakami, T; Chayama, K; Jeong, SC; Kawakami, Y; Kawaoka, T; Mori, N; Takahashi, S; Takaki, S; Uka, K, 2008) |
| "Though chronic hepatitis C was pointed out before, it had been left untreated for about 5 years." | 1.35 | [A case of advanced hepatocarcinoma responding to combination therapy of S-1 and PEG-IFN]. ( Ichikawa, M; Iwakawa, K; Matsumoto, T; Miyauchi, S; Seike, H; Tanaka, Y; Tanisaka, Y; Tsubouchi, E, 2009) |
| "A 66-year-old man was diagnosed with hepatocellular carcinoma with Vp3 by abdominal enhanced CT." | 1.35 | [A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus]. ( Doki, Y; Eguchi, H; Hatano, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Wakasa, K, 2009) |
| "Primary liver cancer with lymph node metastasis was recognized as poor prognosis." | 1.35 | [A case report of combined hepatocellular-cholangiocarcinoma whose lymph node recurrence effectively treated with UFT]. ( Akagi, K; Dono, K; Fujita, J; Hata, T; Hayashi, S; Ikeda, K; Kagawa, Y; Kawanishi, K; Kitada, M; Munakata, K; Shimano, T; Shimizu, J; Takamoto, K; Watanabe, N; Yasumoto, T; Zenitani, M, 2009) |
| "Grade 3 leukocytopenia was observed in 1 patient (8." | 1.35 | Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. ( Dono, K; Kobayashi, S; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamura, M; Noda, T; Takeda, Y; Umeshita, K; Wada, H, 2008) |
| "Advanced hepatocellular carcinoma (HCC) with distant metastases, in particular to the lung, has a poor prognosis." | 1.34 | [Retrospective analysis of clinical results in eight patients with advanced hepatocellular carcinoma with lung metastases treated by TS-1]. ( Asechi, H; Hatano, E; Ikai, I; Nagata, H; Narita, M; Uemoto, S; Yanagida, A; Yasuchika, K, 2007) |
| "4 patients with hepatocellular carcinoma (HCC) and 3 with cholangiocellular carcinoma (CCC) were employed for this study." | 1.34 | S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas. ( Fujita, J; Hoshimoto, S; Ikeda, M; Kato, T; Morise, Z; Sugioka, A, 2007) |
| "We report a case of advanced hepatocellular carcinoma (HCC)." | 1.33 | [Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma providing a good QOL]. ( Amano, M; Fujita, M; Hayashida, H; Higaki, N; Nakagawa, S; Niinobu, T; Nishikawa, Y; Sakon, M; Yamashita, S, 2006) |
| "A standard treatment for hepatocellular carcinoma with extrahepatic metastasis is not established and chemotherapy is ineffective." | 1.32 | [A case of hepatocellular carcinoma with bone metastasis responding to concurrent TS-1/low-dose cisplatin (CDDP) therapy and radiotherapy]. ( Aozasa, S; Fujino, K; Hase, K; Ito, H; Okada, K; Shikina, A; Suganuma, T; Tanaka, M; Terauchi, R; Tsuda, T; Utsunomiya, K, 2004) |
| "Advanced unresectable hepatocellular carcinoma (HCC) was treated with modified pharmacokinetic modulation chemotherapy (PMC)." | 1.31 | [Modified pharmacokinetic modulation chemotherapy (PMC) with medication of UFT and intraarterial infusion of 5-FU for advanced unresectable HCC]. ( Ito, T; Kamachi, H; Kamiyama, T; Kondo, M; Kurauchi, N; Matsushita, M; Nakagawa, T; Nishikawa, M; Ogata, T; Todo, S, 2002) |
| "Spontaneous regression of hepatocellular carcinoma (HCC) is a rare phenomenon." | 1.31 | Complete disappearance of recurrent hepatocellular carcinoma with peritoneal dissemination and splenic metastasis: a unique clinical course after surgery. ( Amano, J; Hanazaki, K; Koide, N; Matsunaga, Y; Shiohara, E; Terasaki, T, 2000) |
| "Ultrasound and CT scan showed that the hepatocellular carcinoma and lung metastatic foci had disappeared completely." | 1.31 | [Complete response of a massive hepatocellular carcinoma with lung metastasis to UFT (DPD inhibitory fluoroprymidines: DIF)]. ( Haseme, E; Kikuchi, K; Ohnishi, Y; Shohkei, O, 2001) |
| "A 56-year-old male had suffered from hepatocellular carcinoma treated by operation, PHoT and TAE since 1994." | 1.30 | [A case of hepatocellular carcinoma with reduction of primary tumor and disappearance of multiple lung metastasis]. ( Ando, A; Asano, N; Bamba, T; Fujiyama, Y; Fukano, M; Inoue, T; Ito, A; Koyama, S; Kubo, M; Sasaki, M; Sato, J; Tsujikawa, T; Yoshioka, U, 1998) |
| "Treatment of hepatocellular carcinoma with bone metastasis is often ineffective, but this is a rare case showing the clinical effectiveness of oral administration of UFT." | 1.29 | [A case of hepatocellular carcinoma with bone metastasis responding to oral administration of UFT]. ( Chao, C; Imada, T; Maehara, T; Matsumoto, A; Miyazaki, T; Morinaga, S; Takehana, T, 1995) |
| "A 65-year-old male with hepatocellular carcinoma was admitted to our hospital." | 1.29 | [A case of hepatocellular carcinoma whose lung metastases and tumor emboli in the inferior vena cava disappeared by oral administration of UFT]. ( Fujiyama, S; Hashiguchi, O; Hayashida, T; Ikebe, M; Noumaru, S; Sato, K; Sato, T; Shibata, J, 1994) |
| "A 74-year-old man was diagnosed as hepatocellular carcinoma (HCC) in the area of S6-7 with tumor thrombus continuously developed from hepatic vein to inferior vena cava (IVC)." | 1.29 | [Vanishing tumor thrombus in IVC after oral administration of UFT and TAE in a patient with HCC; a case report]. ( Ito, T; Koreeda, C; Naitoh, Y; Nakagawa, T; Okuno, H; Seki, T; Shiro, T; Tagawa, Y; Wakabayashi, M; Yamamura, H, 1993) |
| "We found a hepatocellular carcinoma, of about 9 cm in diameter in her right liver lobe." | 1.29 | [A case of giant hepatocellular carcinoma effectively treated by UFT]. ( Hino, F; Urabe, T, 1993) |
| "A 79-year-old female with hepatocellular carcinoma with portal invasion and right adrenal gland metastasis was treated by low dose UFT (200 mg/day)." | 1.29 | [A case of hepatocellular carcinoma with portal invasion and right adrenal gland metastasis showing marked contraction of primary tumor and metastasis with treated by UFT alone]. ( Itoh, Y; Ohkawa, S; Tamai, S; Tarao, K, 1994) |
| "A 77-year-old male with liver cirrhosis was admitted to our hospital for further examination and treatment of liver tumor." | 1.29 | [A case of hepatocellular carcinoma responding to oral administration of UFT]. ( Matsumoto, K; Onodera, H; Otawa, K; Sato, T; Ukai, K, 1996) |
| "In 55 hepatocellular carcinoma patients treated with transcatheter arterial embolization or one shot therapy, the prognosis of patients treated with UFT (group A; n = 23) were historically compared with those of patients treated without UFT (group B; n=32)." | 1.28 | [Therapy of hepatocellular carcinoma with UFT--clinical evaluation of its effect in the combination therapy with transcatheter arterial embolization or one shot therapy]. ( Hayashi, K; Ishikawa, T; Ishinoda, Y; Iwaki, Y; Kisanuki, H; Kitamura, T; Maruyama, T; Nakamura, H; Okamoto, T; Shigehira, M, 1990) |
| "Primary hepatocellular carcinoma complicated by compensatory cirrhosis accompanying pulmonary metastasis was diagnosed from blood biochemistry tests, a high AFP value (390,000 ng/ml) and angiogram findings." | 1.27 | [Almost complete disappearance of metastatic pulmonary tumor and reduction of the main hepatic mass in a case of hepatocellular carcinoma treated with UFT]. ( Hayashi, K; Hidaka, Y; Kitamura, T; Maruyama, T; Nakamura, H; Nakatsuru, K; Shigehira, M; Tsuda, K, 1987) |
| "A diagnosis of hepatocellular carcinoma with extrahepatic portal venous obstruction due to tumor invasion was made." | 1.27 | [A case of hepatocellular carcinoma with extrahepatic portal vein obstruction due to tumor invasion, responsive to oral administration of UFT]. ( Kuroda, K; Maeda, S; Nagase, T; Nakagawa, C; Nakanishi, T; Nishikawa, M; Tokunaga, K, 1987) |
| "Primary hepatoma with infiltration of the inferior vena cava was diagnosed by various imaging techniques and the subject was started on a program of daily oral administrations of 800 mg of tegafur." | 1.27 | [A case of primary hepatoma with marked reduction of the tumor after oral administration of tegafur]. ( Hayashi, K; Ishizaki, J; Kitamura, T; Maruyama, T; Nakamura, H; Shigehira, M; Tsuda, K, 1988) |
| "A total of 850 patients with hepatocellular carcinoma seen during the last 8 years were analyzed retrospectively for survival in relation to treatment and disease stage." | 1.27 | Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. ( Hasegawa, H; Nakajima, Y; Obata, H; Ohnishi, K; Ohtsuki, T; Okazaki, N; Okuda, K; Tomimatsu, M, 1985) |
| "He was diagnosed as having primary hepatocellular carcinoma with bone metastasis by his high titer (111,683 ng/ml) of serum alpha-fetoprotein, computed tomography and abdominal angiography, and so UFT therapy, 400 mg daily, was instituted." | 1.27 | [A case of hepatocellular carcinoma with bone metastasis which responded to oral administration of UFT]. ( Imai, Y; Inada, M; Inui, Y; Kawata, S; Matsuda, Y; Minami, Y; Miyoshi, S; Noda, S; Saito, R; Tamura, S, 1987) |
| " the same therapy in combination with UFT as a maintenance therapy (group B; 8 patients)." | 1.27 | [Clinical evaluation of MMC-mc-chemoembolization therapy and its combination with UFT in hepatocellular carcinoma]. ( Matsuo, SK; Ohmura, K; Ohtsuka, Y; Suzuki, M, 1987) |
| "Pretreatment with tocopheryl nicotinate and indomethacin increased the K values in the control subjects, but was without effect on the K values in patients with primary hepatoma." | 1.26 | Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma. ( Hobara, N; Watanabe, A, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 28 (18.79) | 18.7374 |
| 1990's | 27 (18.12) | 18.2507 |
| 2000's | 48 (32.21) | 29.6817 |
| 2010's | 44 (29.53) | 24.3611 |
| 2020's | 2 (1.34) | 2.80 |
| Authors | Studies |
|---|---|
| Akutsu, N | 1 |
| Kawakami, Y | 3 |
| Numata, Y | 1 |
| Hirano, T | 1 |
| Wagatsuma, K | 1 |
| Ishigami, K | 1 |
| Sasaki, S | 1 |
| Nakase, H | 1 |
| Tohyama, T | 1 |
| Sakamoto, K | 1 |
| Tamura, K | 1 |
| Nakamura, T | 2 |
| Watanabe, J | 3 |
| Wakisaka, H | 1 |
| Takada, Y | 3 |
| Kudo, M | 4 |
| Moriguchi, M | 1 |
| Numata, K | 1 |
| Hidaka, H | 1 |
| Tanaka, H | 3 |
| Ikeda, M | 5 |
| Kawazoe, S | 1 |
| Ohkawa, S | 3 |
| Sato, Y | 1 |
| Kaneko, S | 4 |
| Furuse, J | 3 |
| Takeuchi, M | 2 |
| Fang, X | 1 |
| Date, Y | 1 |
| Okusaka, T | 5 |
| Honda, S | 1 |
| Sawada, K | 1 |
| Hasebe, T | 1 |
| Nakajima, S | 1 |
| Fujiya, M | 1 |
| Okumura, T | 1 |
| Ma, CL | 1 |
| Sun, RJ | 1 |
| Li, J | 1 |
| Miyata, T | 1 |
| Beppu, T | 1 |
| Imamura, YU | 1 |
| Hayashi, H | 2 |
| Imai, K | 1 |
| Chikamoto, A | 1 |
| Yamashita, YI | 1 |
| Fukubayashi, K | 1 |
| Ishiko, T | 1 |
| Baba, H | 1 |
| Zhai, JM | 1 |
| Yin, XY | 1 |
| Lai, YR | 1 |
| Hou, X | 1 |
| Cai, JP | 1 |
| Hao, XY | 1 |
| Liang, LJ | 1 |
| Zhang, LJ | 1 |
| Fushiya, N | 1 |
| Takagi, I | 1 |
| Nishino, H | 1 |
| Akizuki, S | 1 |
| Ohnishi, A | 1 |
| Wang, CF | 1 |
| Wang, YQ | 1 |
| Huang, FZ | 1 |
| Nie, WP | 1 |
| Liu, XY | 1 |
| Jiang, XZ | 1 |
| Tanabe, K | 1 |
| Taura, K | 1 |
| Hatano, E | 2 |
| Koyama, Y | 1 |
| Uemoto, S | 2 |
| Terai, S | 1 |
| Tai, K | 1 |
| Kanbara, Y | 1 |
| Ooka, Y | 1 |
| Chiba, T | 1 |
| Ogasawara, S | 1 |
| Arai, K | 2 |
| Suzuki, E | 2 |
| Tawada, A | 1 |
| Yamashita, T | 4 |
| Kanai, F | 1 |
| Yokosuka, O | 1 |
| Terazawa, T | 1 |
| Kondo, S | 2 |
| Hosoi, H | 1 |
| Morizane, C | 3 |
| Shimizu, S | 2 |
| Mitsunaga, S | 3 |
| Ueno, H | 4 |
| Shiina, S | 1 |
| Nakachi, K | 3 |
| Kojima, Y | 1 |
| Sakamoto, Y | 1 |
| Asaoka, Y | 1 |
| Tateishi, R | 1 |
| Koike, K | 1 |
| Arioka, H | 1 |
| Du, F | 1 |
| Jiang, R | 1 |
| Gu, M | 1 |
| He, C | 1 |
| Guan, J | 1 |
| Fujisaki, S | 1 |
| Takashina, M | 1 |
| Tomita, R | 1 |
| Sakurai, K | 1 |
| Takayama, T | 2 |
| Miki, A | 1 |
| Hirose, T | 1 |
| Minami, T | 1 |
| Morioka, H | 1 |
| Suzuki, T | 1 |
| Otani, T | 1 |
| Kitamura, K | 1 |
| Yoshitani, S | 1 |
| Ishikawa, Y | 1 |
| Nishihira, T | 1 |
| Lv, Y | 1 |
| Liang, R | 1 |
| Hu, X | 1 |
| Liu, Z | 1 |
| Liao, X | 1 |
| Lin, Y | 1 |
| Yuan, C | 1 |
| Liao, S | 1 |
| Li, Q | 1 |
| Zhang, J | 2 |
| Li, Y | 1 |
| Ishizuka, M | 1 |
| Kubota, K | 1 |
| Nemoto, T | 1 |
| Shimoda, M | 1 |
| Kato, M | 1 |
| Iso, Y | 1 |
| Tago, K | 1 |
| Kou, P | 1 |
| Zhang, Y | 1 |
| Shao, W | 1 |
| Zhu, H | 1 |
| Wang, H | 1 |
| Kong, L | 1 |
| Yu, J | 1 |
| Uka, K | 1 |
| Aikata, H | 2 |
| Mori, N | 2 |
| Takaki, S | 2 |
| Azakami, T | 1 |
| Kawaoka, T | 2 |
| Jeong, SC | 1 |
| Takahashi, S | 3 |
| Chayama, K | 5 |
| Takagi, S | 1 |
| Misawa, R | 2 |
| Iinuma, N | 1 |
| Uchikawa, Y | 1 |
| Ueshima, K | 3 |
| Nagai, T | 1 |
| Tatsumi, C | 1 |
| Ueda, T | 1 |
| Hatanaka, K | 1 |
| Kitai, S | 1 |
| Ishikawa, E | 1 |
| Inoue, T | 2 |
| Hagiwara, S | 2 |
| Minami, Y | 3 |
| Chung, H | 2 |
| Anegawa, G | 1 |
| Sonoda, H | 1 |
| Inoue, F | 1 |
| Tsuchiya, A | 2 |
| Imai, M | 2 |
| Kamimura, H | 2 |
| Togashi, T | 2 |
| Watanabe, K | 3 |
| Seki, K | 2 |
| Ishikawa, T | 6 |
| Ohta, H | 3 |
| Yoshida, T | 6 |
| Kamimura, T | 2 |
| Matsuda, M | 1 |
| Shiba, S | 1 |
| Asakawa, M | 1 |
| Kono, H | 1 |
| Fujii, H | 1 |
| Chen, FG | 1 |
| Wang, JJ | 1 |
| Xue, Q | 1 |
| Tanisaka, Y | 1 |
| Seike, H | 1 |
| Matsumoto, T | 1 |
| Tanaka, Y | 3 |
| Tsubouchi, E | 1 |
| Miyauchi, S | 1 |
| Iwakawa, K | 1 |
| Ichikawa, M | 1 |
| Hatano, H | 1 |
| Kobayashi, S | 8 |
| Nagano, H | 14 |
| Tomokuni, A | 2 |
| Tomimaru, Y | 1 |
| Murakami, M | 1 |
| Marubashi, S | 12 |
| Eguchi, H | 7 |
| Takeda, Y | 8 |
| Tanemura, M | 5 |
| Wakasa, K | 2 |
| Doki, Y | 6 |
| Mori, M | 7 |
| Shimizu, J | 2 |
| Hayashi, S | 1 |
| Dono, K | 9 |
| Yasumoto, T | 1 |
| Zenitani, M | 1 |
| Munakata, K | 1 |
| Watanabe, N | 1 |
| Takamoto, K | 1 |
| Kagawa, Y | 1 |
| Hata, T | 1 |
| Kawanishi, K | 1 |
| Ikeda, K | 4 |
| Fujita, J | 2 |
| Akagi, K | 1 |
| Kitada, M | 1 |
| Shimano, T | 1 |
| Kitagawa, T | 1 |
| Monden, M | 9 |
| Yamamoto, K | 1 |
| Matsuyama, S | 1 |
| Sonoda, K | 1 |
| Murakami, S | 1 |
| Higaki, K | 1 |
| Nasu, K | 1 |
| Kikuno, M | 1 |
| Tang, TC | 2 |
| Man, S | 2 |
| Lee, CR | 1 |
| Xu, P | 2 |
| Kerbel, RS | 3 |
| Yokoo, H | 2 |
| Kamiyama, T | 4 |
| Nakanishi, K | 3 |
| Tahara, M | 2 |
| Fukumori, D | 1 |
| Kamachi, H | 3 |
| Matsushita, M | 3 |
| Todo, S | 3 |
| Hsu, CH | 3 |
| Shen, YC | 2 |
| Lin, ZZ | 1 |
| Chen, PJ | 1 |
| Shao, YY | 2 |
| Ding, YH | 1 |
| Hsu, C | 2 |
| Cheng, AL | 3 |
| Enomoto, H | 1 |
| Ishii, A | 1 |
| Imanishi, H | 1 |
| Saito, M | 1 |
| Iwata, Y | 1 |
| Sakai, Y | 1 |
| Iwai, T | 1 |
| Yoh, K | 1 |
| Takashima, T | 1 |
| Yoshikawa, S | 1 |
| Aizawa, N | 1 |
| Yamamoto, T | 3 |
| Ikeda, N | 1 |
| Shimomura, S | 1 |
| Iijima, H | 1 |
| Hirota, S | 1 |
| Nishiguchi, S | 1 |
| Miyano, M | 1 |
| Kurai, O | 1 |
| Hiramatsu, S | 1 |
| Yamasaki, T | 1 |
| Sasaki, E | 1 |
| Adachi, K | 1 |
| Oka, H | 1 |
| Yamaguchi, M | 1 |
| Takita, M | 1 |
| Haji, S | 1 |
| Kimura, M | 1 |
| Arao, T | 1 |
| Nishio, K | 1 |
| Park, AM | 1 |
| Munakata, H | 1 |
| Francia, G | 1 |
| Hashimoto, K | 1 |
| Emmenegger, U | 1 |
| Ishii, H | 1 |
| Kim, SJ | 2 |
| Han, SW | 1 |
| Oh, DY | 1 |
| Yi, NJ | 1 |
| Kim, YJ | 1 |
| Im, SA | 1 |
| Yoon, JH | 1 |
| Kang, GH | 1 |
| Suh, KS | 1 |
| Bang, YJ | 1 |
| Jang, JJ | 1 |
| Kim, TY | 1 |
| Yamada, D | 1 |
| Wada, H | 9 |
| Umeshita, K | 11 |
| Hsu, CY | 1 |
| Yu, CW | 1 |
| Hu, FC | 1 |
| Chen, BB | 1 |
| Wei, SY | 1 |
| Shih, TT | 1 |
| Iwamoto, H | 1 |
| Torimura, T | 1 |
| Hashimoto, O | 1 |
| Inoue, K | 2 |
| Kurogi, J | 1 |
| Niizeki, T | 1 |
| Kuwahara, R | 1 |
| Abe, M | 1 |
| Koga, H | 1 |
| Yano, H | 1 |
| Ueno, T | 1 |
| Sata, M | 3 |
| Ueno, M | 1 |
| Kameda, R | 1 |
| Miyakawa, K | 2 |
| Tamura, S | 3 |
| Kanazawa, A | 1 |
| Yamamoto, N | 1 |
| Morinaga, S | 2 |
| Mizukami, T | 1 |
| Taniguchi, M | 1 |
| Kakisaka, T | 1 |
| Lee, SJ | 1 |
| Lee, J | 2 |
| Park, SH | 1 |
| Park, JO | 1 |
| Park, YS | 1 |
| Kang, WK | 1 |
| Yim, DS | 1 |
| Lim, HY | 1 |
| Endo, M | 1 |
| Aoki, T | 2 |
| Tsuchida, A | 1 |
| Katsura, Y | 1 |
| Kawamoto, K | 2 |
| Huang, CC | 1 |
| Lin, SD | 1 |
| Kagawa, K | 1 |
| Honda, Y | 1 |
| Nakahara, T | 1 |
| Tanaka, M | 3 |
| Naeshiro, N | 1 |
| Miyaki, D | 1 |
| Nagaoki, Y | 1 |
| Hiramatsu, A | 1 |
| Waki, K | 1 |
| Hyogo, H | 1 |
| Arihiro, K | 1 |
| Sanetou, H | 1 |
| Terashima, T | 1 |
| Sunagozaka, H | 1 |
| Shimakami, T | 1 |
| Mizukoshi, E | 1 |
| Sakai, A | 1 |
| Honda, M | 1 |
| Ito, T | 3 |
| Okubo, K | 1 |
| Shiomi, M | 1 |
| Narita, M | 2 |
| Morita, K | 1 |
| Takeuchi, A | 1 |
| Kanazawa, H | 1 |
| Takeyama, T | 1 |
| Hashizume, K | 1 |
| Shibahara, H | 1 |
| Nishimura, D | 1 |
| Katada, N | 1 |
| Katano, Y | 1 |
| Goto, H | 1 |
| Furukawa, K | 1 |
| Hama, N | 1 |
| Akita, H | 1 |
| Makino, H | 1 |
| Kametaka, H | 1 |
| Seike, K | 1 |
| Koyama, T | 1 |
| Imamura, Y | 1 |
| Baba, Y | 1 |
| Tahara, K | 1 |
| Kubozono, O | 1 |
| Ogura, Y | 1 |
| Maenohara, S | 1 |
| Moriya, H | 1 |
| Kurauchi, N | 1 |
| Nakagawa, T | 2 |
| Kondo, M | 2 |
| Ogata, T | 1 |
| Nishikawa, M | 2 |
| Yuan, WJ | 1 |
| Chen, FY | 1 |
| Zhang, GY | 1 |
| Takemura, M | 1 |
| Osugi, H | 1 |
| Lee, S | 1 |
| Taguchi, S | 1 |
| Kaneko, M | 1 |
| Fukuhara, K | 1 |
| Fujiwara, Y | 2 |
| Nishizawa, S | 1 |
| Kinoshita, H | 1 |
| Matsushita, A | 1 |
| Hanazaki, K | 2 |
| Noike, T | 1 |
| Nakagawa, K | 1 |
| Nakata, T | 1 |
| Nomura, K | 1 |
| Kobayashi, A | 1 |
| Miwa, S | 1 |
| Miyagawa, S | 1 |
| Kawasaki, S | 1 |
| Takemoto, R | 2 |
| Shakado, S | 2 |
| Yamashita, N | 2 |
| Nishi, H | 2 |
| Fukumori, K | 3 |
| Fukuizumi, K | 2 |
| Miyahara, T | 2 |
| Sakai, H | 2 |
| Yasumori, K | 2 |
| Muranaka, T | 2 |
| Takami, Y | 2 |
| Saitsu, H | 2 |
| Suganuma, T | 1 |
| Terauchi, R | 1 |
| Shikina, A | 1 |
| Aozasa, S | 1 |
| Utsunomiya, K | 1 |
| Fujino, K | 1 |
| Ito, H | 1 |
| Okada, K | 1 |
| Tsuda, T | 1 |
| Hase, K | 1 |
| Sakon, M | 5 |
| Inagaki, H | 1 |
| Ito, N | 1 |
| Kurokawa, T | 1 |
| Owa, Y | 1 |
| Kotake, K | 1 |
| Arikawa, T | 1 |
| Horikoshi, I | 1 |
| Tsubamoto, M | 1 |
| Nagata, H | 2 |
| Suzumura, K | 1 |
| Nonami, T | 1 |
| Nakamura, M | 6 |
| Ota, H | 3 |
| Damdinsuren, B | 4 |
| Yang, Y | 1 |
| Miyamoto, A | 7 |
| Nakamori, S | 3 |
| Seo, HY | 1 |
| Choi, JG | 1 |
| Sul, HR | 1 |
| Sung, HJ | 1 |
| Park, KH | 1 |
| Choi, IK | 1 |
| Oh, SC | 1 |
| Yoon, SY | 1 |
| Seo, JH | 1 |
| Choi, CW | 1 |
| Kim, BS | 1 |
| Shin, SW | 1 |
| Kim, YH | 1 |
| Kim, JS | 1 |
| Yoshioka, S | 2 |
| Kato, H | 2 |
| Noda, T | 3 |
| Terakura, M | 1 |
| Ikawa, S | 1 |
| Kubota, D | 1 |
| Katsuragi, K | 1 |
| Ohba, K | 1 |
| I, S | 1 |
| Matsuyama, M | 1 |
| Hasegawa, K | 1 |
| Ijichi, M | 1 |
| Matsuyama, Y | 1 |
| Imamura, H | 1 |
| Sano, K | 1 |
| Sugawara, Y | 1 |
| Kokudo, N | 1 |
| Makuuchi, M | 1 |
| Yamashita, S | 1 |
| Niinobu, T | 1 |
| Nakagawa, S | 2 |
| Amano, M | 1 |
| Nishikawa, Y | 1 |
| Hayashida, H | 1 |
| Higaki, N | 1 |
| Fujita, M | 3 |
| Asechi, H | 1 |
| Yanagida, A | 1 |
| Yasuchika, K | 1 |
| Ikai, I | 1 |
| Miyake, Y | 1 |
| Iwasaki, Y | 1 |
| Shiraha, H | 1 |
| Sakaguchi, K | 1 |
| Shiratori, Y | 1 |
| Di Meglio, G | 1 |
| Fazio, N | 1 |
| Nolè, F | 1 |
| Della Vigna, P | 1 |
| Lorizzo, K | 1 |
| Goldhirsch, A | 1 |
| Farris, A | 1 |
| Zavaglia, C | 1 |
| Prisco, C | 1 |
| Pinzello, G | 1 |
| Morise, Z | 1 |
| Sugioka, A | 1 |
| Hoshimoto, S | 1 |
| Kato, T | 1 |
| Han, CJ | 1 |
| Ueda, H | 1 |
| Kida, Y | 1 |
| Fukuchi, H | 1 |
| Ichinose, M | 1 |
| Ohya, T | 1 |
| Kikuchi, S | 1 |
| Anttila, MI | 1 |
| Sotaniemi, EA | 1 |
| Kairaluoma, MI | 1 |
| Mokka, RE | 1 |
| Sundquist, HT | 1 |
| Onji, M | 2 |
| Yamashita, Y | 3 |
| Horiike, N | 1 |
| Kanaoka, M | 1 |
| Ohta, Y | 2 |
| Hattori, M | 1 |
| Takenaka, K | 1 |
| Yoshida, K | 1 |
| Nishizaki, T | 1 |
| Korenaga, D | 1 |
| Hiroshige, K | 1 |
| Ikeda, T | 1 |
| Sugimachi, K | 1 |
| Saitoh, S | 1 |
| Koida, I | 1 |
| Tsubota, A | 1 |
| Arase, Y | 3 |
| Kumada, H | 3 |
| Chao, C | 1 |
| Imada, T | 1 |
| Takehana, T | 1 |
| Miyazaki, T | 1 |
| Maehara, T | 1 |
| Matsumoto, A | 1 |
| Maruhashi, Y | 1 |
| Hirose, S | 1 |
| Nakagawa, H | 1 |
| Satomura, Y | 1 |
| Hayakawa, Y | 1 |
| Demachi, H | 1 |
| Miwa, A | 1 |
| Nakanuma, Y | 1 |
| Shibata, J | 1 |
| Hayashida, T | 1 |
| Ikebe, M | 1 |
| Sato, K | 1 |
| Noumaru, S | 1 |
| Fujiyama, S | 1 |
| Sato, T | 4 |
| Hashiguchi, O | 1 |
| Miyazaki, K | 1 |
| Yakushiji, H | 1 |
| Kitahara, K | 1 |
| Sasatomi, E | 1 |
| Tsutsumi, N | 1 |
| Hirohashi, Y | 1 |
| Iwanaga, A | 1 |
| Iyama, A | 1 |
| Fukagawa, H | 1 |
| Miyagawa, H | 1 |
| Kamioka, N | 1 |
| Kohara, H | 1 |
| Yuube, R | 1 |
| Takahashi, T | 2 |
| Nakatoh, H | 1 |
| Kawada, M | 1 |
| Utsunomiya, T | 1 |
| Izumiyama, F | 1 |
| Akimori, T | 1 |
| Tagawa, Y | 1 |
| Seki, T | 1 |
| Shiro, T | 1 |
| Wakabayashi, M | 1 |
| Yamamura, H | 1 |
| Koreeda, C | 1 |
| Naitoh, Y | 1 |
| Okuno, H | 1 |
| Urabe, T | 1 |
| Hino, F | 1 |
| Itoh, Y | 1 |
| Tamai, S | 1 |
| Tarao, K | 1 |
| Itsubo, M | 1 |
| Tsurumachi, T | 1 |
| Yamamoto, H | 2 |
| Honda, I | 1 |
| Watanabe, S | 1 |
| Yamada, S | 1 |
| Jingu, K | 1 |
| Satomi, D | 1 |
| Onodera, H | 1 |
| Ukai, K | 1 |
| Matsumoto, K | 1 |
| Otawa, K | 1 |
| Une, Y | 2 |
| Nishibe, M | 1 |
| Shimamura, T | 1 |
| Haneda, T | 1 |
| Uchino, J | 2 |
| Kudo, K | 1 |
| Arakawa, A | 1 |
| Takagi, Y | 1 |
| Nishimura, R | 1 |
| Takahashi, M | 1 |
| Asano, N | 1 |
| Fukano, M | 1 |
| Kubo, M | 1 |
| Sato, J | 1 |
| Ito, A | 1 |
| Tsujikawa, T | 1 |
| Ando, A | 1 |
| Sasaki, M | 1 |
| Yoshioka, U | 1 |
| Koyama, S | 1 |
| Fujiyama, Y | 1 |
| Bamba, T | 1 |
| Kume, M | 1 |
| Ogoshi, S | 1 |
| Hisa, N | 1 |
| Yoshida, S | 1 |
| Yamashita, F | 1 |
| Ando, E | 1 |
| Yano, Y | 1 |
| Kato, O | 1 |
| Fukuda, H | 1 |
| Kusaba, T | 1 |
| Tanikawa, K | 2 |
| Kazumori, H | 1 |
| Sizuku, T | 1 |
| Uchida, Y | 1 |
| Moritani, M | 1 |
| Yamamoto, S | 1 |
| Ichida, T | 2 |
| Ishimoto, Y | 2 |
| Yokoyama, J | 2 |
| Nomoto, M | 1 |
| Ebe, Y | 1 |
| Usuda, H | 1 |
| Naito, M | 1 |
| Asakura, H | 2 |
| Sadamoto, Y | 1 |
| Koujima, M | 1 |
| Itaba, S | 1 |
| Miyagi, Y | 1 |
| Imamura, M | 1 |
| Motosato, K | 1 |
| Inoue, Y | 1 |
| Siomichi, S | 1 |
| Amagase, Y | 1 |
| Terasaki, T | 1 |
| Shiohara, E | 1 |
| Matsunaga, Y | 1 |
| Koide, N | 1 |
| Amano, J | 1 |
| Kishimoto, S | 1 |
| Gotoh, M | 1 |
| Haseme, E | 1 |
| Shohkei, O | 1 |
| Ohnishi, Y | 1 |
| Kikuchi, K | 1 |
| Sugitani, S | 1 |
| Tsuboi, Y | 1 |
| Genda, T | 1 |
| Sugahara, S | 1 |
| Uehara, K | 1 |
| Inayoshi, J | 1 |
| Ono, T | 1 |
| Yamanoi, A | 1 |
| Nazmy El Assal, O | 1 |
| Kohno, H | 1 |
| Nagasue, N | 1 |
| Aguayo, A | 1 |
| Patt, YZ | 1 |
| Maruyama, T | 4 |
| Nozue, M | 1 |
| Aoyagi, H | 1 |
| Sakamoto, T | 1 |
| Fukue, M | 1 |
| Matsui, S | 1 |
| Kodaira, Y | 1 |
| Monma, E | 1 |
| Shidara, S | 1 |
| Ikezawa, K | 1 |
| Shimakura, S | 1 |
| Mayr, AC | 1 |
| Kurihara, M | 1 |
| Shirakabe, H | 1 |
| Izumi, T | 1 |
| Miyasaka, K | 1 |
| Ariyama, J | 1 |
| Watanabe, A | 2 |
| Hobara, N | 2 |
| Nagashima, H | 1 |
| Kojima, J | 2 |
| Kamata, T | 2 |
| Monna, T | 2 |
| Okada, S | 1 |
| Okazaki, N | 4 |
| Nose, H | 1 |
| Yoshimori, M | 1 |
| Aoki, K | 1 |
| Shindo, K | 1 |
| Mizuno, T | 1 |
| Sawada, Y | 1 |
| Iwamoto, S | 1 |
| Yurino, N | 1 |
| Fujii, S | 1 |
| Murai, N | 1 |
| Okuno, F | 1 |
| Kotake, H | 1 |
| Mashiba, H | 1 |
| Hori, Y | 1 |
| Isogawa, S | 1 |
| Saho, M | 1 |
| Yoshida, H | 1 |
| Yokoyama, K | 1 |
| Watanabe, M | 1 |
| Kitamura, T | 3 |
| Nakamura, H | 3 |
| Hayashi, K | 3 |
| Shigehira, M | 3 |
| Iwaki, Y | 1 |
| Okamoto, T | 1 |
| Ishinoda, Y | 1 |
| Kisanuki, H | 1 |
| Ito, Y | 1 |
| Ogasawara, K | 1 |
| Nagafuchi, E | 1 |
| Matsuoka, S | 1 |
| Misawa, K | 1 |
| Sato, N | 1 |
| Nakajima, Y | 2 |
| Miyamoto, K | 1 |
| Inagaki, Y | 1 |
| Miyairi, M | 1 |
| Nakatsuru, K | 1 |
| Tsuda, K | 2 |
| Hidaka, Y | 1 |
| Nakanishi, T | 2 |
| Nagase, T | 1 |
| Nakagawa, C | 1 |
| Maeda, S | 1 |
| Kuroda, K | 1 |
| Tokunaga, K | 1 |
| Suenaga, M | 1 |
| Ishizaki, J | 1 |
| Nakamura, I | 1 |
| Murashima, N | 1 |
| Takeuchi, K | 1 |
| Nakajima, M | 1 |
| Yoshiba, A | 2 |
| Irimoto, M | 2 |
| Horie, Y | 1 |
| Hirai, K | 1 |
| Shimizu, M | 1 |
| Inoue, J | 1 |
| Kubo, Y | 1 |
| Hara, Y | 1 |
| Okumura, M | 1 |
| Hirayama, C | 1 |
| Ogawa, N | 1 |
| Imaoka, S | 1 |
| Sasaki, Y | 1 |
| Shibata, T | 1 |
| Ishikawa, O | 1 |
| Ohigashi, H | 1 |
| Furukawa, H | 1 |
| Koyama, H | 1 |
| Iwanaga, T | 1 |
| Hirose, N | 1 |
| Gunji, T | 1 |
| Okuda, K | 1 |
| Ohtsuki, T | 1 |
| Obata, H | 1 |
| Tomimatsu, M | 1 |
| Hasegawa, H | 2 |
| Ohnishi, K | 1 |
| Yoshino, M | 2 |
| Hijikata, A | 1 |
| Kondo, H | 1 |
| Mori, K | 1 |
| Fuse, M | 1 |
| Hizikata, A | 1 |
| Kawakami, H | 1 |
| Ando, B | 1 |
| Koga, S | 1 |
| Ibayashi, H | 1 |
| Ando, S | 1 |
| Inada, M | 1 |
| Kawata, S | 2 |
| Miyoshi, S | 2 |
| Imai, Y | 2 |
| Saito, R | 1 |
| Noda, S | 2 |
| Inui, Y | 1 |
| Matsuda, Y | 1 |
| Ohmura, K | 1 |
| Suzuki, M | 1 |
| Matsuo, SK | 1 |
| Ohtsuka, Y | 1 |
| Oguma, S | 1 |
| Sakai, K | 1 |
| Sato, R | 1 |
| Ouchi, K | 1 |
| Owada, Y | 1 |
| Saitoh, R | 1 |
| Tarui, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Sorafenib Plus Tegafur/Uracil for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma[NCT00464919] | Phase 2 | 50 participants (Anticipated) | Interventional | 2007-04-30 | Completed | ||
| Efficacy and Safety of Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection[NCT05161143] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-12-31 | Not yet recruiting | ||
| Human Liver Explants for HIF-1 Alpha- Analysis/Comparison[NCT00866957] | 180 participants (Actual) | Observational | 2006-02-28 | Completed | |||
| A Randomized Phase II Trial of Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma or Who Are Unfit for Standard Therapy[NCT01097083] | Phase 2 | 20 participants | Interventional | 2010-04-30 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for tegafur and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Pharyngeal metastasis following living-donor liver transplantation for hepatocellular carcinoma: a case report and literature review.
Topics: Allografts; Biopsy; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Drug Combi | 2020 |
[Complete remission of hepatocellular carcinoma with multiple lung metastases by oral administration of tegafur/uracil].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 2013 |
Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Ch | 2017 |
[A successful case of systemic chemotherapy followed by liver resection for advanced hepatocellular carcinoma with highly vascular invasion and multiple pulmonary metastases].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Combinat | 2011 |
[Surgical resection and S-1 administration for the treatment of hepatocellular carcinoma].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Combinat | 2012 |
[Complete disappearance with oral UFT administration of recurrent hepatocellular carcinoma of the remnant liver and multiple lung metastasis after hepatic resection].
Topics: Administration, Oral; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2003 |
[Recent progress in chemotherapy for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 2004 |
[Recent developments in systemic chemotherapy for hepatocellular carcinoma].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Capecitabi | 2008 |
Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Humans; Liver Neop | 2008 |
Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepa | 2001 |
Nonsurgical treatment of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Chemoemboli | 2001 |
[Chemotherapy of gastrointestinal tumors (review of the literature)].
Topics: Ancitabine; Carcinoma, Hepatocellular; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fl | 1978 |
23 trials available for tegafur and Hepatocellular Carcinoma
| Article | Year |
|---|---|
S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Diarrhea; Double-Blind Method; Dru | 2017 |
A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2014 |
Transarterial infusion chemotherapy with cisplatin plus S-1 for hepatocellular carcinoma treatment: a phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2014 |
Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chem | 2014 |
Administration of adjuvant oral tegafur/uracil chemotherapy post hepatocellular carcinoma resection: A randomized controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemot | 2016 |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Benzenesul | 2010 |
Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Carcinoma, Hepatocellular; Disease-Free Sur | 2010 |
A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carci | 2011 |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2011 |
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonate | 2012 |
[Effect of indomethacin on natural killer(NK) cell and T lymphocyte subsets from patients with hepatocellular carcinoma].
Topics: Adjuvants, Immunologic; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Fem | 2000 |
Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antidotes; Antineoplastic Agents; Antineoplastic Combined | 2006 |
Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy | 2006 |
Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carc | 2007 |
A phase II study of tegafur plus uracil or tegafur alone for the treatment of advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female | 2008 |
Adjuvant chemotherapy with tegafur/uracil administration after transcatheter arterial chemoembolization for advanced hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Combined Mo | 2008 |
A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Drug Combinations; Embolization, The | 1995 |
A pharmacological pilot study: application of an intermittent schedule of oral uracil and ftorafur (UFT) for hepatocellular carcinoma patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Female; Hepatectomy; Humans | 1996 |
A crossover study of oral administration of UFT in chronic liver disease: comparison of continuous and intermittent schedules.
Topics: Administration, Oral; Aged; Area Under Curve; Carcinoma, Hepatocellular; Chronic Disease; Cross-Over | 1998 |
Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Combina | 2001 |
[Randomized trial-comparing UFT and FT in the treatment of advanced hepatocellular carcinoma (second report: well controlled study on patients with transcatheter arterial embolization) Osaka Research Society for Liver, Gallbladder and Pancreas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 1992 |
[Randomized trial comparing UFT and FT-207 in the treatment of advanced hepatocellular carcinoma (first report: well controlled study on the patients for whom transcatheter arterial embolization could not be applied) Osaka Research Society for Liver, Gall
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Embolization | 1990 |
[Clinical value of OK-432 immunotherapy after one-shot arterial infusion of anti-cancer agents in the treatment of hepatocellular carcinoma--a randomized study].
Topics: Administration, Oral; Biological Products; Carcinoma, Hepatocellular; Clinical Trials as Topic; Huma | 1988 |
114 other studies available for tegafur and Hepatocellular Carcinoma
| Article | Year |
|---|---|
A case of hepatocellular carcinoma with long-term survival by multidisciplinary treatment for cranial and skeletal muscle metastases.
Topics: Carcinoma, Hepatocellular; Drugs, Investigational; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; | 2022 |
Tegafur-uracil-induced rapid development of advanced hepatic fibrosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Biopsy; Carcinoma, Hepatocellular; Di | 2017 |
Short-term effect of metronomic chemotherapy of low-dose Tegafur on patients with primary hepatic carcinoma after radiofrequency ablation.
Topics: Administration, Metronomic; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; | 2018 |
A 12-year Recurrence-free Survival After Multidisciplinary Treatment for a Patient With Combined Hepatocellular-Cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chol | 2019 |
Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellula | 2013 |
Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Asian People; C | 2013 |
Association between reversal of multidrug resistance by methyl jasmonate and P-glycoprotein ATPase activity in hepatocellular carcinoma.
Topics: Acetates; Adenosine Triphosphate; Animals; Antineoplastic Agents; Antineoplastic Combined Chemothera | 2013 |
[A case of hepatocellular carcinoma (Vp4)-combination therapy prolonged survival in a patient with advanced hepatocellular carcinoma with a tumor thrombus in the portal vein trunk].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality | 2013 |
The clinical application of 320-detector row CT in transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma.
Topics: Adult; Aged; Angiography, Digital Subtraction; Biopsy; Camptothecin; Carcinoma, Hepatocellular; Chem | 2015 |
[Treatment of repeat TACE plus S-1 for multiple intrahepatic recurrence of hepatoma and gastric cancer].
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Com | 2014 |
[Six-year survival with recurrent intrahepatic cholangiocarcinoma achieved by simple S-1 administration].
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocel | 2015 |
Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2014 |
Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 2008 |
[Two cases of advanced hepatocellular carcinoma (HCC) effectively treated by oral UFT administration].
Topics: Administration, Oral; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carc | 2008 |
Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Combination | 2008 |
[A case report--complete disappearance of multiple intrahepatic recurrences and portal thrombus in a case of hepatocellular carcinoma treated with UFT-E].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans | 2009 |
Successful treatment of multiple lung metastases of hepatocellular carcinoma by combined chemotherapy with docetaxel, cisplatin and tegafur/uracil.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 2009 |
Complete remission of multiple recurrent hepatocellular carcinomas by oral administration of enteric-coated tegafur/uracil in a patient with huge hepatocellular carcinoma extending to the inferior vena cava after hepatic resection: analysis of mRNA expres
Topics: Administration, Oral; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality T | 2009 |
[Inhibition of angiogenesis of LCI-D20 hepatocellular carcinoma by metronomic chemotherapy of S-1].
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Drug Combinations; F | 2009 |
[A case of advanced hepatocarcinoma responding to combination therapy of S-1 and PEG-IFN].
Topics: Angiography; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 2009 |
[A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
[A case report of combined hepatocellular-cholangiocarcinoma whose lymph node recurrence effectively treated with UFT].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neo | 2009 |
[A case of complete response to S-1 therapy for multiple pulmonary recurrences of hepatocellular carcinoma after hepatic resection].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Combinations; Hepatectomy; Hu | 2009 |
[A case of multiple pulmonary and remnant liver metastases of hepatocellular carcinoma (HCC) after partial hepatic resection remarkably responding to S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; | 2010 |
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; | 2010 |
[A successful case of S-1 chemotherapy for bilateral pulmonary recurrence of hepatocellular carcinoma long after hepatectomy].
Topics: Administration, Oral; Carcinoma, Hepatocellular; Drug Combinations; Hepatectomy; Humans; Liver Neopl | 2010 |
[A case of hepatocellular carcinoma with autoimmune hepatitis showing marked reduction of tumors by oral administration of UFT-E].
Topics: Administration, Oral; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biom | 2010 |
[A case of hepatocellular carcinoma with portal vein thrombus(Vp3)and lung metastases(stage IVB),which responded completely to treatment with Tegafur/Uracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Liv | 2010 |
The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Pr | 2011 |
Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2010 |
Combination chemotherapy with S-1 and platinum in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocel | 2010 |
[A long-term survival case of hepatocellular carcinoma with bone metastasis and inferior vena cava tumor thrombus successfully treated with multidisciplinary therapy].
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Carcinoma, Hepatocellular; Chemoembolization, Thera | 2010 |
Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, He | 2011 |
[Retroperitoneal metastasis of hepatocellular carcinoma - a case report].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Combinat | 2011 |
[A case of UFT-induced complete response against multiple lung metastases of hepatocarcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neopl | 2011 |
[A case of complete response to interferon-α and S-1 combination therapy for multiple pulmonary recurrences of hepatocellular carcinoma after hepatic resection].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; | 2011 |
[A case of successful surgical resection followed by S-1 administration for hepatocellular carcinoma with lung metastases and a tumor thrombus into right atrium].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Dr | 2011 |
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Mon | 2012 |
[A case of advanced hepatocellular carcinoma with lung, brain and lymph node metastases recurred 8 years after hepatectomy successfully treated by operation, radiation and systemic chemotherapy using S-1/CDDP].
Topics: Adult; Antimetabolites, Antineoplastic; Brain Neoplasms; Carcinoma, Hepatocellular; Combined Modalit | 2012 |
[A case report of S-1 monotherapy for advanced hepatocellular carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Combinations; Fatal Outcome; | 2012 |
[A case of successful treatment of granulocyte colony-stimulating factor producing hepatocellular carcinoma accompanying type B hepatitis with tegafur-uracil].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, H | 2012 |
[A case of diffuse hepatocellular carcinoma(Vp4) treated by right hepatic trisegmentectomy and multidisciplinary therapy regimens].
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Combinations; Fatal Outcome; Female; Hepa | 2012 |
[A patient with hepatocellular carcinoma with intraperitonial lymph node metastases in whom oral UFT treatment was markedly effective].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 2002 |
[Modified pharmacokinetic modulation chemotherapy (PMC) with medication of UFT and intraarterial infusion of 5-FU for advanced unresectable HCC].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combina | 2002 |
[Remnant gastric cancer in which prolonged no change status was maintained with low-dose TS-1--a case report].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellul | 2003 |
[A case of hepatocellular carcinoma treated with TS-1].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Combinations; Humans; Liver N | 2003 |
[A case of hepatocellular carcinoma with bone metastasis responding to concurrent TS-1/low-dose cisplatin (CDDP) therapy and radiotherapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; B | 2004 |
[A case of giant hepatocellular carcinoma treatable with radio frequent ablation therapy after effective UFT administration].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 2004 |
[A case of long-term survivor with multiple pulmonary metastases of HCC after hepatic resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Combinati | 2004 |
[A case of hepatocellular carcinoma with bone metastasis treated by TS-1 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Hepatocellular; Cisplatin | 2005 |
[A case of HCC with inferior caval vein tumor thrombus and multiple pulmonary metastases that remarkably responded to combination therapy of TS-1 and interferon-alpha].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2005 |
[A successful surgical treatment for solitary pulmonary and adrenal metastases after hepatic resection to hepatocellular carcinoma--a case report].
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2005 |
[A case of synchronous gastric and hepatocellular carcinoma successfully treated by TS-1 and hepatic arterial infusion chemotherapy (HAI) of low-dose CDDP].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 2005 |
[S-1 treatment against advanced HCC].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 2006 |
A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Dihydrouracil Dehy | 2006 |
[Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma providing a good QOL].
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2006 |
[Retrospective analysis of clinical results in eight patients with advanced hepatocellular carcinoma with lung metastases treated by TS-1].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Administration Schedul | 2007 |
Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2007 |
Successful treatment with low-dose oral chemotherapy in a patient with metastatic hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 2007 |
S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2007 |
Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2008 |
[Clinical evaluation of chemotherapeutic agents in the treatment of primary liver cancer].
Topics: Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluor | 1982 |
Pharmacokinetics of ftorafur after intravenous and oral administration.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Half-Life; Human | 1983 |
[Sequential changes in blood concentrations of tegafur and 5-FU during oral administration of fine granules of tegafur in patients with primary liver cancer].
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans | 1982 |
Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Che | 1995 |
[A case of hepatocellular carcinoma with bone metastasis responding to oral administration of UFT].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Hep | 1995 |
[A case of poorly differentiated hepatic cell carcinoma which showed 90% decrease in size after chemotherapy with intraarterial infusion of mitomycin C and oral administration of tegafur].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 1994 |
[A case of hepatocellular carcinoma whose lung metastases and tumor emboli in the inferior vena cava disappeared by oral administration of UFT].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 1994 |
[A comparative study on the serum and tissue 5-FU concentrations in patients with hepatocellular carcinoma after preoperative oral administration of UFT and 5'-DFUR].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 1994 |
[A case of advanced hepatocellular carcinoma, in which the tumor almost disappeared by orally administered UFT].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; | 1993 |
[Vanishing tumor thrombus in IVC after oral administration of UFT and TAE in a patient with HCC; a case report].
Topics: Aged; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Combinations; Embolization, Therape | 1993 |
[A case of giant hepatocellular carcinoma effectively treated by UFT].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tum | 1993 |
[A case of hepatocellular carcinoma with portal invasion and right adrenal gland metastasis showing marked contraction of primary tumor and metastasis with treated by UFT alone].
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocell | 1994 |
[The present status of chemotherapy for hepatocellular carcinoma].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 1993 |
[A case of hepatocellular carcinoma with reduction of primary tumor and disappearance of multiple lung metastasis].
Topics: Administration, Oral; Carcinoma, Hepatocellular; Drug Combinations; Humans; Liver Neoplasms; Lung Ne | 1996 |
[A case of hepatocellular carcinoma responding to oral administration of UFT].
Topics: Administration, Oral; Aged; alpha-Fetoproteins; Biomarkers; Carcinoma, Hepatocellular; Drug Combinat | 1996 |
[A case of advanced hepatocellular carcinoma responding to suppository of Tegafur].
Topics: alpha-Fetoproteins; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Humans; Liver Neopla | 1998 |
[A case of hepatocellular carcinoma with reduction of primary tumor and disappearance of multiple lung metastasis].
Topics: Administration, Oral; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepat | 1998 |
[Complete disappearance of metastatic pulmonary tumors in a case of hepatocellular carcinoma treated with UFT].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 1998 |
[A case of giant hepatocellular carcinoma effectively treated with UFT].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 1998 |
Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 1999 |
[A case of advanced hepatocellular carcinoma with lung and bone metastases effectively treated by orally administered UFT].
Topics: Administration, Oral; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2000 |
Complete disappearance of recurrent hepatocellular carcinoma with peritoneal dissemination and splenic metastasis: a unique clinical course after surgery.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Drug Thera | 2000 |
Advanced hepatocellular carcinoma with distant metastases, successfully treated by a combination therapy of alpha-interferon and oral tegafur/uracil.
Topics: Administration, Oral; Adult; Angiography; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2000 |
[Complete response of a massive hepatocellular carcinoma with lung metastasis to UFT (DPD inhibitory fluoroprymidines: DIF)].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Combinations; Humans; Liver Neoplasms; | 2001 |
[A case of spindle cell type hepatocellular carcinoma responding to hepatic intra-arterial infusion chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dru | 2002 |
Futraful therapy on liver cancer.
Topics: Administration, Oral; Adult; Aged; Alkaline Phosphatase; Carcinoma, Hepatocellular; Drug Administrat | 1977 |
[Characteristic pharmacodynamic in 1-(2-tetrahydrofuryl)-5-fluorouracil metabolism and its clinical efficacy in patients with primary hepatoma (author's transl)].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Li | 1978 |
Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Indomethacin; Kinetics; Liver Cirrhosis; Liver Neop | 1979 |
Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy.
Topics: alpha-Fetoproteins; Analysis of Variance; Antineoplastic Agents; Ascites; Bilirubin; Carcinoma, Hepa | 1992 |
Hepatocellular carcinoma response to low-dose oral tegafur.
Topics: Administration, Oral; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Remissi | 1991 |
[Rupture of hepatocellular carcinoma with multiple pulmonary metastasis successfully treated by transcatheter arterial embolization (TAE) of tumor: a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, | 1991 |
[A case of hepatocellular carcinoma in an elderly patient that improved upon combination therapy of Lentinan and Tegafur].
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcino | 1990 |
[Therapy of hepatocellular carcinoma with UFT--clinical evaluation of its effect in the combination therapy with transcatheter arterial embolization or one shot therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality T | 1990 |
[Study on the pharmacokinetics of UFT in patients with hepatocellular carcinoma associated with cirrhosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo | 1989 |
[Successful therapy with tegafur and lentinan after TAE for hepatocellular carcinoma--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Embolization, Therapeutic | 1989 |
[Almost complete disappearance of metastatic pulmonary tumor and reduction of the main hepatic mass in a case of hepatocellular carcinoma treated with UFT].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fem | 1987 |
[A case of hepatocellular carcinoma with extrahepatic portal vein obstruction due to tumor invasion, responsive to oral administration of UFT].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 1987 |
[5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; Fluoro | 1987 |
[A case of primary hepatoma with marked reduction of the tumor after oral administration of tegafur].
Topics: Administration, Oral; Carcinoma, Hepatocellular; Drug Administration Schedule; Humans; Liver Neoplas | 1988 |
[Effects and side effects of long-term administration of oral antitumor agents in patients with hepatocellular carcinoma--especially, relation to aggravation of liver function].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality T | 1987 |
[Anticancer effect of UFT in intrahepatic recurrence with tumor embolus in the left portal vein after hepatectomy of hepatoma--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Hepatectomy; Humans | 1988 |
[Risk factors for side effects of long-term administration of 5-fluorouracil derivatives in patients with hepatocellular carcinoma associated with liver cirrhosis--relationship with serum concentration of anti-tumor agents and side effect].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Brain Diseases; Carcinoma, Hepatocell | 1988 |
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Fluorouracil; | 1985 |
A controlled study of intravenous doxorubicin versus oral tegafur in patients with hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Carcinoma, Hepatocellular; Doxorubicin; Drug Evaluation; Female; Humans; | 1985 |
Phase II study of co-administration of uracil and tegafur (UFT) in hepatocellular carcinoma. Tokyo Liver Cancer Chemotherapy Study Group.
Topics: Administration, Oral; Aged; Carcinoma, Hepatocellular; Drug Combinations; Female; Humans; Liver Neop | 1985 |
[Blood level of 5-fluorouracil (5-FU) by oral administration of 1-hexylcarbamoyl-5-fluorouracil (HCFU) and tegafur in patients with hepatocellular carcinoma].
Topics: Administration, Oral; Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; | 1985 |
[Systemic chemotherapy of hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy | 1986 |
[Maintenance chemotherapy by UFT after trans-arterial embolization for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy | 1986 |
[An unresectable case of hepatoma completely disappearing after oral administration of an anticancer drug (UFT)].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 1986 |
[A case of hepatocellular carcinoma with bone metastasis which responded to oral administration of UFT].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Hepatocellular; Humans; L | 1987 |
[Clinical evaluation of MMC-mc-chemoembolization therapy and its combination with UFT in hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Adminis | 1987 |
[FT, 5-FU and uracil concentrations of the blood, bile and tissue of hepatoma with liver cirrhosis after oral administration of UFT].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bile; Carcinoma, Hepatocellula | 1987 |
Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Drug Therapy, Computer-Assisted; Fluorouracil; Humans; In Vitro Tec | 1987 |